| Project/Area Number |
24791285
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 神経芽腫 / 内用療法 / カフェイン / 131I-MIBG |
|---|
| Research Abstract |
I-131 meta-iodobenzylguanidine (MIBG) has been used to treat patients with high-risk neuroblastoma. I-131 MIBG accumulate into tumor cells and has an anti-tumor effect by high-energy beta-irradiation. Caffeine is classified as purine alkaloids, and has anti-tumor effect in tumor cells by inhibition of DNA-repair. This study was performed whether I-131 MIBG interacted with caffeine for human neuroblastoma cell line SK-N-SH. Cells were treated with caffeine at concentrations as high as 40 mM, and the anti-tumor effect of caffeine was concentrate-dependent. However, uptake of I-131 MIBG into neuroblastoma cells treated by caffeine was reduced independently of the load timing. These results suggest that high-dose caffeine has anti-tumor effect, but the anti-tumor effect by combined I-131 MIBG and caffeine will not be enhanced, probably by decreasing uptake of I-131 MIBG.
|
